La cadena de opciones muestra datos clave de las opciones de acciones de Saverone 2014 a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Saverone 2014..

Saverone 2014 (NASDAQ:SVRE) Bolsa, Cadena de Opciones

Saverone 2014

Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.

Movimiento de acciones

AEHL

AMBC

BTOG

CCCS

DGICA

EHAB

FFIC

FMTO

IXHL

RNAC

SDHC

SVRE

TNMG

VERO

VINC

VNOM

WORX

Acciones en alza y en caída antes del mercado: descubre qué impulsó los mayores movimientos bursátiles del día.

Acciones de Venus Concept (VERO) se disparan un 200%; aquí están 20 acciones que se mueven en premercado

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

Levi sorprende al mercado con ganancias trimestrales mejores de lo esperado y una perspectiva 2025 que mantiene sin cambios.

Acciones de Levi Strauss suben un 10%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

Leerink Swann analyst Mani Foroohar downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform and lowers the price target from $45 to $10.

Downgrades

Price Target

Analyst Ratings

SRPT

Leerink Swann Downgrades Sarepta Therapeutics to Market Perform, Lowers Price Target to $10

Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) experienced an 8% year-over-year slip in Chinese sales during June.
What Happened: The company experienced a slip in sales as rivals like Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>), Xpeng Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NASDAQ">XPEV</a>), etc. gained in sales, Bloomberg reported <a href="https://www.bloomberg.com/news/articles/2025-07-21/life-atop-china-s-car-market-is-starting-to-look-shaky-for-byd">on</a> Monday.
Analysts from investment banks like Deutsche Bank expect the company to hit 5 million wholesale units in 2025, the report suggests, while Morgan Stanley lowered its projection to 5.3 million.
BYD would need to sell over 560,000 units a month to meet its annual delivery projection for 2025 of 5.5 million units sold, which could prove difficult amid electric vehicle price war scrutiny by the Chinese Communist Party, according to the report. 
However, BYD's overseas sales are on track to reach the 800,000 unit milestone the company set out to deliver this year, with 60% of that figure already achieved by BYD, the report suggests.
Why It Matters: The news comes as BYD has adopted an aggressive pricing strategy in the Chinese market with discounted prices amid fierce competition in the sector, which has <a href="https://www.benzinga.com/news/topics/25/06/45715047/byds-aggressive-pricing-triggers-ev-rat-race-stock-tumbles-authorities-voice-concern">raised concerns within</a> the Chinese government.
Despite scrutiny, BYD released <a href="https://www.benzinga.com/markets/tech/25/07/46187880/tesla-rival-byd-launches-11000-long-range-trim-of-its-best-selling-seagull-ev-as-price-war-heats-up">a long-range version</a> of its best-selling EV, the Seagull EV, for $11,000 in the market, as well as the <a href="https://www.benzinga.com/markets/tech/25/06/45855643/tesla-rival-byd-launches-15000-seal-06-sedan-as-chinas-ev-price-war-heats-up">Seal 06 EV</a> for $15,000 in China.
Elsewhere, BYD's fellow Chinese automakers Zeekr Intelligent Technologies Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) and Neta have been accused of <a href="https://www.benzinga.com/markets/asia/25/07/46512860/tesla-rival-geelys-zeekr-neta-inflated-sales-data-in-china-through-insurance-scheme-amid-zero-mileage-used-cars-row-report">inflating sales data </a>through insurance schemes in the country, according to reports in Chinese state media.
Elsewhere, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has recorded <a href="https://www.benzinga.com/markets/tech/25/07/46409821/tesla-rebounds-in-china-with-12-3k-weekly-registrations-highest-2nd-week-ever">over 12.3k insured registrations</a> for the second week of July, which is a strong rebound for Elon Musk's EV giant after a poor start to the month in China.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46512836/elon-musks-tesla-announces-3-million-model-3-units-sold-worldwide">Elon Musk&#8217;s Tesla Announces 3 Million Model 3 Units Sold Worldwide</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

BYDDF

BYDDY

TSLA

XIACY

XPEV

Tesla Rival BYD's Domestic Sales Slip 8% In June, Analysts Slash Annual Delivery Projections Amid EV Price War Scrutiny

Fiserv's Clover Launches PracticePay To Streamline Healthcare Payments For Small And Medium-Sized Healthcare Providers

Jefferies analyst Brian Tanquilut upgrades Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) from Hold to Buy and lowers the price target from $6.25 to $6.

Upgrades

AVAH

Jefferies Upgrades Aveanna Healthcare Hldgs to Buy, Lowers Price Target to $6

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $28 to $20.

JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $20

Three Democrat-led states have decided to revoke or limit health coverage for immigrants without legal status, a move that could have significant consequences for the affected individuals and the healthcare system at large.
What Happened: The states of&nbsp;California,&nbsp;Illinois and&nbsp;Minnesota&nbsp;have recently made the decision to end or reduce health coverage for immigrants without legal status,&nbsp;<a href="https://apnews.com/article/medicaid-immigrants-california-illinois-minnesota-ice-f43d5681a6e9d45d274790c2eae716ee">reported</a>&nbsp;the Associated Press. This change will affect&nbsp;hundreds of thousands of immigrants.
The programs have proven to be much more costly than initially projected, a significant concern given the states&#8217; current and future multibillion-dollar deficits. As a result, Illinois, Minnesota, and California have opted to cut back on the programs to save money.
Adult immigrants aged 42 to 64 without legal status in Illinois have been cut off from health care, resulting in estimated savings of $404 million. In Minnesota, all adult immigrants have been removed from the state program, saving nearly $57 million. California plans to halt new adult enrollments starting in 2026, projecting savings of over $3 billion over several years.
These cuts — backed by Democratic governors who once championed expanded health coverage for immigrants — are already discouraging people from seeking care, largely out of fear of arrest or deportation.
Health care providers have raised concerns about the effects of these cuts, especially the risk that fear of arrest or deportation may prevent immigrants from seeking medical care. This avoidance of preventive services could ultimately result in higher long-term costs, as more immigrants may require treatment at safety-net hospitals.
See Also: <a href="https://benzinga.com/crypto/cryptocurrency/25/07/46495773/shiba-inu-rallies-10-in-1-week-can-it-go-higher" target="_blank" rel="noreferrer noopener">Shiba Inu Rallies 10% In 1 Week: Can It Go Higher?</a>
Why It Matters: The decision to cut health coverage for immigrants without legal status comes&nbsp;at a time when the&nbsp;Trump administration has been taking steps to tighten immigration policies and enforcement.
Earlier this month, the Trump administration&nbsp;<a href="https://www.benzinga.com/news/politics/25/07/46363638/trump-ends-head-start-program-for-illegal-aliens-moves-to-cut-clinton-era-postsecondary-aid-and-other-federal-benefits">announced</a>&nbsp;that undocumented immigrants would no longer be eligible for various federal programs, including the Head Start program and several other federal benefits and programs. This decision, combined with the recent cuts in health coverage, could have a significant impact on the well-being of immigrants without legal status.
Moreover, the Trump administration&#8217;s decision to&nbsp;share 79 million Medicaid recipients&#8217; private <a href="https://www.benzinga.com/news/legal/25/07/46247689/palantir-reportedly-assisting-trump-administrations-doge-to-compile-americans-personal-data">health data</a> with Immigration and Customs Enforcement (ICE)&nbsp;has sparked legal challenges from several states, including California. The recent cuts in health coverage for immigrants without legal status may further exacerbate the already contentious relationship between the federal government and these states.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46381096/trump-administration-ordered-by-judge-to-stop-immigration-arrests-without-probable-cause-in-southern-california-report">Trump Administration Ordered By Judge To Stop Immigration Arrests Without Probable Cause In Southern California: Report</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Medicaid Cuts In 3 Democrat-Led States Strip Health Coverage From Undocumented Immigrants Amid Budget Crunch

Rogers Communications Upsizes Cash Tender Offers To $1.4B To Purchase Eight Series Of US Dollar Debt Securities

<ul>
<li>NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populations</li>
<li>Reflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19</li>
<li>New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a significant impact on cancer patients, including serious delays or even cessation of cancer treatment and prolonged complications</li>
</ul>

Biotech

Health Care

General

IVVD

Invivyd Says Updated National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology For Cancer-related Infections Now Recommend The Use Of Available Monoclonal Antibodies For Pre-exposure Prophylaxis Of Covid-19

VMAR

Octillion Power Systems And Vision Marine Technologies Expand Supplier Agreement; Octillion To Manufacture Vision-Branded Battery Packs For E-Motion 180# Electric Outboard System For US Market Distribution

CRGO

Freightos Expands South Asia Reach As SriLankan Cargo Integration Unlocks Digital Access To Colombo And Indian Subcontinent Markets

<ul>
<li>NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populations</li>
<li>Reflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19</li>
<li>New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a significant impact on cancer patients, including serious delays or even cessation of cancer treatment and prolonged complications &nbsp;</li>
</ul>
WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced the June 20, 2025 updated National Comprehensive Cancer Network&#xAE; (NCCN&#xAE;) Clinical Practice Guidelines in Oncology (NCCN Guidelines&#xAE;) for the Prevention and Treatment of Cancer-Related Infections now recommend the use of available monoclonal antibodies for pre-exposure prophylaxis of COVID-19. The NCCN Guidelines advise clinicians to refer to guidance from Infectious Diseases Society of America (IDSA), Centers for Disease Control and Prevention (CDC), or U.S. Food and Drug Administration for available monoclonal antibody options. This recommendation reflects the growing alignment among key organizations - including IDSA and CDC - reinforcing the critical role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19.
New research titled <a href="https://www.globenewswire.com/Tracker?data=h65lcNho57CRsdPWCAseEoSTMEOKZuhYODPFZLo9vnpS23gmi7nBPPJZCyBj9aVo17Urkf-i9GZDmVEj5rnjfb1bYRiBa46rX49zgiCDP2dTK5iaeTPfe82RtmswJ6inz09g9TXvzpYllfyAHnGOg5aF-pC9w60FUkOfKiEQE9HKelyZJfBo2Qh8JQtzXXe1Is4oET1t524aOkC-_wOw4LAlVeKgD7XLDNF2ItF12YeroKrTzW1fujxPriJQ5ZpF">Risk Factors for COVID-19–Related Hospitalization and Death in Patients With Cancer</a> published online on July 17, 2025 in JAMA Oncology reflects why prevention of SARS-CoV-2 is important for people with cancer. The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) provides critical insights into the long-term impact of SARS-CoV-2 infection in these individuals.
Over a two-year period, the NCCAPS study followed 1,572 eligible adult patients with cancer who also had COVID-19. The data revealed high risk of severe disease as evidenced by the rate of hospitalization, treatment delays, and mortality within 90 days among patients undergoing chemotherapy or those with hematologic malignancies, consistent with previous studies. Notably, of the 290 patients that were initially hospitalized for COVID-19, 31 patients had a second admission for sequelae of COVID-19 within 30 days of their initial admission. Over 50% of all cancer treatment disruptions in the cohort were directly attributed to COVID-19, especially during the early phase of infection. These disruptions raised concerns about continuity of care and long-term impacts on patient outcomes. These data highlight the importance of continued surveillance and prevention strategies in populations at highest risk for COVID-19 complications.

Invivyd Says Updated NCCN Guidelines For Prevention And Treatment Of Cancer-Related Infections Now Recommend Use Of Available Monoclonal Antibodies For Pre-Exposure Prophylaxis Of COVID-19

AstraZeneca's TAGRISSO Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Overall Survival For Patients With 1st-Line Locally Advanced Or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer

Jefferies analyst Joseph Gallo initiates coverage on AvePoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) with a Buy rating and announces Price Target of $22.

Initiation

AVPT

Jefferies Initiates Coverage On AvePoint with Buy Rating, Announces Price Target of $22

<ul>
<li>Agrees to issue approximately $10 Million Convertible Notes at $13 per share, a 198% premium to July 18 close $189 million raised year-to-date through hallmark DeFi/TradFi Accretion Flywheel strategy</li>
</ul>

BTCS

BTCS Inc. Reports $242.2M In ETH and Cash Holdings, Issues $10M In Convertible Notes At 198% Premium As Part of DeFi/TradFi Accretion Flywheel Strategy

QBTS

D-Wave Quantum Announces Results Of New Study Highlighting Potential For Quantum Optimization To Create Value Across Industries

AVTR

Avantor Names Emmanuel Ligner As President And CEO, Succeeding Michael Stubblefield Effective August 18

SPGI

S&P Dow Jones Indices To Acquire ARC Research, Terms Not Disclosed

TNXP

Tonix Pharma's Tonix Medicines Launches Move Fibro Forward Campaign To Bring Awareness And Support To Individuals Impacted By Fibromyalgia, Debilitating Condition With No New FDA-Approved Treatments In Over 15 Years

ORKA

Oruka Therapeutics Receives FDA Clearance For Its IND Application For Phase 2a Trial Of ORKA-001 In Psoriasis

Management

BENF

Beneficient Appoints Thomas O. Hicks As Chairman And James G. Silk As Interim Chief Executive Officer Amid Leadership Restructure

Press Releases

SaverOne Granted New Patent in the United States  Further Expanding its IP Portfolio

SaverOne Regains Compliance with Nasdaq Minimum Bid Price Requirement

Earnings

SaverOne Reports Full Year 2024 Results

SaverOne Signs New Distribution Agreement in Canada

Contracts

SaverOne Signs Expands Cooperation with Cemex: Signs Agreement with Cemex Czech Republic for Deployment of Its Driver Distraction Prevention System

SaverOne Further Broadens its Global Expansion with a new Agreement with CEMEX Germany

SaverOne Signs Preliminary Agreement with Leading European  ADAS Technology Provider for Sensor Fusion Collaboration

Legal

SaverOne Granted New US Patent Advancing Sensor Fusion Capabilities for Driver Safety

This Week Undercard $3 Stocks: SNYR, SONN, LGPS, SVRE, PRSO Making Strategic Moves

SaverOne Signs Sales & Marketing Agreement with US-based TOJ Jax Targeting Major US Trucking Fleets

AMZN

COST

LGPS

PRSO

SNYR

SONN

Astrotech

Cemtrex

Digital Ally

Electro-Sensors

Focus Universal

AEye

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

SMX (Security Matters) Public Limited Company - Class A Ordinary Shares

SMX (Security Matters)

Sobr Safe

ScanTech AI Systems

SaverOne 2014 Ltd. - American Depositary Shares

Universal Security Instruments, Inc. Common Stock

Universal Security

VerifyMe

Screenshot 2024-03-28 at 5.39.42 PM

VLVLY

SaverOne Inks Major OEM Deal With IVECO – Distracted Driving Software To Be Installed In All Its Light, Medium And Heavy Commercial Vehicles

Comments

Saverone 2014

Saverone 2014 (SVRE) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL